Heather Preston is an experienced healthcare investor and company builder, with more than 30 years of industry experience. She is currently a Senior Advisor to TPG Biotech and serves on the Boards of Oxford Biomedica (OXB:LSE), Oxford Nanopore Technologies (ONT:LSE), and Azura Opthalmics. Previously, she was a Managing Partner of Pivotal BioVentures and a Firm Partner and Managing Director of TPG Biotech. She also held investing roles at JP Morgan Partners and New Enterprise Associates. Prior to her investing career, Dr. Preston spent five years at McKinsey & Co, where she was a leader of their pharmaceutical and medical products consulting practice. Dr. Preston has an undergraduate degree in biochemistry from the University of London and a medical degree from the University of Oxford. Dr. Preston completed a post-doctoral fellowship in molecular biology at the Dana Farber Cancer Institute, Harvard University and trained in Internal Medicine at the Massachusetts General Hospital and subspecialized in Gastroenterology and Hepatology at UCSF. During her academic medical career, she was the recipient of a Fulbright Scholarship, a Fulbright Cancer Research Scholarship, a Harlech Scholarship and a Science and Engineering Research Council Post-Doctoral Fellowship Award.